DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

The Changing Face of Motor Symptom Treatment in Parkinson’s Disease

High unmet need for new drugs to address motor complications in Parkinson’s disease (PD) has attracted a number of developers to this space; since 2015, four new brands targeting motor symptoms have launched in the United States, and we estimate another eight will launch within the next few years. Together, we expect these therapies could more than triple the size of the PD market and reshape the once-stable PD treatment algorithm.

The infographic below combines DRG Epidemiology, surveyed U.S. neurologists’ opinions, and U.S. claims data to provide insight into some of the ways the Parkinson’s Disease treatment algorithm may change over the next few years. 


For more information on the Parkinson’s Disease market, browse our recent reports here.